# HIT earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/HIT) · [Earnings tab](https://www.lopjlb.com/stock/HIT?tab=earnings) Updated: 2026-07-20T01:51:15 Quarters analyzed: 6 ## Cross-quarter narrative Across six quarters Health In Tech moved from a modest Q4‑2024 revenue dip and vague guidance to a sustained high‑growth trajectory, posting 71% YoY revenue expansion in 2025 and guiding $45‑$50M for FY‑2026. Gross margins improved from a decline in Q4‑2024 to stable 67% in Q1‑2025 and then to stronger adjusted EBITDA margins by Q2‑2025, reflecting disciplined cost control and higher‑margin AI‑driven underwriting. The company accelerated AI and platform investments, launching beta large‑group underwriting, AI‑backed underwriting, and a suite of automation tools, while expanding its broker network from a few hundred to 885 partners. Despite these gains, recurring fears surfaced: market demand volatility from rising health‑care costs, heavy reliance on third‑party AI and broker adoption, execution risk around product rollouts, and regulatory‑pricing uncertainty. New concerns emerged around pricing models for marketplace services and the pace of blockchain partnership execution. Milestones shifted from early IT upgrades and IPO completion to delivering stop‑loss programs, data‑driven solutions, and a $7M PIPE, though several initiatives remain at risk or pending. Overall the narrative shows accelerating growth and margin improvement, balanced by persistent external and execution risks. ## Latest CallCard · Q1 Health In Tech is investing $7M PIPE capital to expand broker distribution, add carriers, upgrade AI tech and launch a 3‑year rate‑stabilization program, while guiding FY2026 revenue $45‑50M despite Q1 loss and higher expenses. **Guidance:** maintained — Management reiterated FY2026 revenue guidance of $45M‑$50M. **Tone:** mgmt 0.7 · Q&A pressure 0.6 · divergence 0.3 Prepared remarks emphasized large market opportunity, low broker penetration and deliberate investment in sales, carriers and technology. ### Demand visibility Introduced contracted revenue metric to improve revenue visibility Contracted revenue of $22.9M for the remaining three quarters was disclosed, and platform placed plan value (PPPV) of $82M was reported to show future revenue flow. ### Margins / costs Higher operating expenses reduced margins, resulting in negative adjusted EBITDA Sales & marketing rose to 26% of revenue, G&A 39%, R&D 10%; adjusted EBITDA was –$1.3M versus +$1.2M YoY. ### Capital allocation $7M PIPE proceeds allocated to growth initiatives Funds will be used to expand the sales team, add carrier partners, enhance AI‑driven technology architecture with Ciklum, and advance new product offerings. ### Milestones - **PIPE financing** [delivered]: Completed March 2026, providing $7M gross proceeds. - **Sales distribution expansion** [on_track]: Planning to hire 2‑3 additional sales reps to increase broker outreach. - **Carrier network expansion** [on_track]: Targeting greater carrier diversity to improve underwriting options. - **Ciklum technology partnership** [on_track]: Engaged to enhance front‑ and back‑end platform functionality. - **eDIYBS platform update** [delivered]: Released new interface, workflow and AI features with positive broker feedback. - **3‑year rate stabilization program** [at_risk]: Market testing slated late Q2‑Q3 2026; first quote expected in Q2 but not yet signed. - **Beta of data‑driven solution** [on_track]: Initial testing to begin in Q2 2026, integrating psychological and claims data. - **New KPI framework (contracted revenue & PPPV)** [delivered]: Implemented to give clearer visibility into future revenue. ### Fears / risks - **Adoption risk**: Broker and employer uptake of the new pre‑configured plans and 3‑year rate program may be slower than anticipated. - **Sales cycle length**: Longer sales cycles for large‑group customers could postpone revenue recognition. - **Carrier pricing variability**: Fluctuations in carrier underwriting criteria may affect pricing competitiveness at renewal. - **Technology integration**: Reliance on Ciklum partnership and AI enhancements introduces execution risk. - **Regulatory/forward‑looking risk**: Forward‑looking statements subject to uncertainties that could cause actual results to differ. - **Cash burn**: Increased operating expenses and negative adjusted EBITDA raise cash‑flow concerns. - **Competitive pressure**: Large number of insurance brokers and incumbents could limit market share gains. - **Revenue recognition timing**: Revenue spread over 12‑month contracts may mask near‑term performance. ### Key quotes > “Our penetration of the broker pool remains well below 1/10 of 1%, which highlights the significant runway potential ahead” > “we penetrated a very, very small portion of the overall broker market. And so we've hired -- our intention to hire 2 to 3 sales reps” — Zain Hasan > “As of March 31, our contracted revenue for the remaining 3 quarters of this year total will be around $22.9 million.” > “We don't require an upfront deposit.” — Julia Qian ## Quarter one-liners - **2026 Q1:** Health In Tech is investing $7M PIPE capital to expand broker distribution, add carriers, upgrade AI tech and launch a 3‑year rate‑stabilization program, while guiding FY2026 revenue $45‑50M despite Q1 loss and higher expenses. - **2025 Q4:** Health In Tech posted 71% revenue growth in 2025, expanded its broker network to 885 partners, launched larger‑group underwriting and new stop‑loss programs, and guided 2026 revenue to $45‑$50M while emphasizing AI and platform expansion. - **2025 Q3:** HealthInTech Q3 2025 saw 90% YoY revenue growth, launched large-employer underwriting, tested a three-year rate‑hold program, signed an LOI for a blockchain claims platform, and announced a Davos InsurTech Summit. - **2025 Q2:** Health in Tech posted Q2 2025 revenue of $9.3 M, up 86% YoY, expanded its partner network to 778 firms, highlighted an AI‑driven underwriting platform and upcoming product beta tests while noting broad market uncertainty. - **2025 Q1:** Health in Tech posted a 56% YoY revenue jump to $8M, strong pre‑tax profit, expanded broker network and AI‑backed underwriting beta, while highlighting a Q3 rollout and a new DialCare tele‑health partnership. - **2024 Q4:** Health In Tech posted a modest Q4 revenue dip, boosted cash to $7.8M, moderated growth in 2024 and outlined a 2025 rollout of its large‑business underwriting platform while expanding its leadership team. ## Theme arcs - **Revenue Growth** (improving): YoY revenue rose from a dip to 71% growth and FY‑2026 guidance of $45‑$50M - **Margin Improvement** (improving): Gross margin stabilized and adjusted EBITDA rose sharply by Q2‑2025 - **AI/Tech Development** (improving): Progressed from beta underwriting to AI‑driven automation and data‑driven solutions - **Broker Network Expansion** (improving): Partners grew from 778 to 885, supporting distribution - **Market Demand Uncertainty** (deteriorating): Rising health‑care costs and employer plan‑selection delays persisted - **Regulatory & Pricing Volatility** (stable): Regulatory changes and potential rate hikes repeatedly cited - **Execution Risk** (new): Product beta timing, rate‑hold program, and blockchain LOI introduced new execution challenges - **Pricing Model Uncertainty** (new): Unfinalized marketplace pricing created revenue timing risk - **Competitive Pressure** (stable): Entrenched carriers and broker adoption remain ongoing challenges ## Guidance path 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/HIT`